Treatment of migraine headaches with presynaptic neurotoxin
The present invention provides a method for treating a patient for migraine headache, including symptoms associated with migraine head ache, such as migraine associated vertigo, which comprises administering to the patient a therapeutically effective amount of an invertebrate presynaptic neurotoxin, e.g. Botulinum toxin in a pharmaceutically safe form.
1. A method of treating a patient with a migraine headache caused by a traumatic brain injury comprising extramuscularly administering a therapeutically effective amount of a suitably diluted Botulinum toxin in a pharmaceutically safe form to the patient in need thereof to reduce the migraine headache caused by the traumatic brain injury.
2. The method of claim 1 , wherein the Botulinum toxin is a Botulinum toxin A and/or a Botulinum toxin B.
3. The method of claim 2 , wherein the Botulinum toxin A is onabotulinumtoxin A.
4. The method of claim 1 , wherein the Botulinum toxin comprises an Endotoxin.
5. The method of claim 4 , wherein the Endotoxin is an endopeptidase.
6. A method of treating a patient with a migraine headache caused by a traumatic brain injury comprising extramuscularly administering a therapeutically effective amount of a suitably diluted Botulinum toxin in a pharmaceutically safe form to the head of a patient in need thereof to reduce the migraine headache caused by a traumatic brain injury.
7. The method according to claim 6 , wherein the Botulinum toxin is a Botulinum toxin A and/or a Botulinum Toxin B.
8. The method according to claim 7 , wherein the Botulinum toxin A is onabotulinumtoxin A.
9. The method according to claim 6 , wherein the Botulinum toxin is an Endotoxin.
10. The method of claim 9 , wherein the Endotoxin is an endopeptidase.
11. A method of treating a patient with a migraine headache caused by a traumatic brain injury comprising extramuscularly administering to a patient in need thereof a therapeutically effective amount of a Botulinum toxin in a pharmaceutically safe form to the head and/or upper neck of the patient in need thereof to reduce the migraine headache caused by the traumatic brain injury;
administration being on the sites of the trigeminal cervical system, enabling axonal transport of the Botulinum toxin from distal to central sites; and
the administration comprising extramuscular injection of the Botulinum toxin of suitable dilution (a) over the aponeurotic fascia to enable the Botulinum toxin to diffuse into distal sensory nerves, in order to concentrate the Botulinum toxin over the occipital-parietal-frontal head region and/or (b) to emerging exit points of nerves including foraminal sites for enabling the Botulinum toxin access to concentrated nerve bundles at exit points of the foramina.
12. The method according to claim 11 , wherein the administration to the aponeurotic fascia includes dilution of about 4-10 cc of normal saline per 100 units of Botulinum toxin.
13. The method according to claim 11 , wherein the administrations according to (b) and (c) are at a dilution of about 1 cc normal saline per 100 units of Botulinum toxin.
14. The method according to claim 11 , wherein the Botulinum toxin is Botulinum toxin A and/or a Botulinum toxin B.
15. The method according to claim 14 , wherein the Botulinum toxin A is onabotulinumtoxin A.
16. The method according to claim 11 , wherein the Botulinum toxin is an Endotoxin.
17. The method according to claim 16 , wherein the Endotoxin is an endopeptidase.
18. The method according to claim 11 , wherein the emerging nerve exit points are one or more of the Great auricular, Auriculotemporal, Supraorbital, Supratrochlear, Infratrochlear, Infraorbital or Mental nerve exit points.
19. The method according to claim 1 , wherein the Botulinum toxin is extramuscularly administered into aponeurotic fascia and/or to emerging nerve exit points in the face and/or neck.
20. The method according to claim 19 , wherein the emerging nerve exit points are one or more of the Great auricular, Auriculotemporal, Supraorbital, Supratrochlear, Infratrochlear, Infraorbital or Mental nerve exit points.
21. The method according to claim 6 , wherein the Botulinum toxin is extramuscularly administered into aponeurotic fascia and/or to emerging nerve exit points in the face and/or neck.
22. The method according to claim 21 , wherein the emerging nerve exit points are one or more of the Great auricular, Auriculotemporal, Supraorbital, Supratrochlear, Infratrochlear, Infraorbital or Mental nerve exit points.